US 12,459,916 B2
Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
Gerald Beddies, Leverkusen (DE); Adrian Foster, Sandwich (GB); Ulrich Bothe, Berlin (DE); Nicole Schmidt, Wuppertal (DE); Ulf Boemer, Glienicke (DE); Reinhard Nubbemeyer, Berlin (DE); and Maria De Lourdes Mottier, Langenfeld (DE)
Assigned to Bayer Pharma Aktiengesellschaft, Berlin (DE)
Filed by Bayer Pharma Aktiengesellschaft, Berlin (DE)
Filed on Jan. 7, 2022, as Appl. No. 17/570,550.
Application 17/570,550 is a continuation of application No. 16/306,235, abandoned, previously published as PCT/EP2017/062876, filed on May 29, 2017.
Claims priority of application No. 16172544 (EP), filed on Jun. 1, 2016.
Prior Publication US 2022/0204474 A1, Jun. 30, 2022
Int. Cl. C07D 401/12 (2006.01); C07D 405/14 (2006.01)
CPC C07D 401/12 (2013.01) [C07D 405/14 (2013.01)] 22 Claims
 
1. A method for the treatment, and/or prophylaxis of allergic diseases in a dog, comprising administering to the dog a compound of the general formula (I)

OG Complex Work Unit Chemistry
wherein
R1 is C1-C6-alkyl, wherein the C1-C6-alkyl group is unsubstituted or mono- or polysubstituted identically or differently by halogen, hydroxyl, an unsubstituted or mono- or poly-halogen-substituted C3-C6-cycloalkyl, or an R6, R7SO2, R7SO or R8O group, or a group selected from:

OG Complex Work Unit Chemistry
wherein * represents the bonding site of the group to the rest of the molecule;
R2 and R3 always have the same definition and are either hydrogen or C1-C6-alkyl;
R4 is halogen, cyano, an unsubstituted or a singly or multiply, identically or differently substituted C1-C6-alkyl or an unsubstituted or a singly or multiply, identically or differently substituted C3-C6-cycloalkyl, and the substituents are selected from the group of halogen and hydroxyl;
R5 is hydrogen, halogen or an unsubstituted or mono- or poly-halogen-substituted C1-C6-alkyl;
R6 is an unsubstituted or mono- or di-methyl-substituted monocyclic saturated heterocycle having 4 to 6 ring atoms, which contains a heteroatom or a heterogroup from the group of O, S, SO and SO2;
R7 is C1-C6-alkyl, wherein the C1-C6-alkyl group is unsubstituted or mono- or polysubstituted identically or differently by halogen, hydroxyl or C3-C6-cycloalkyl;
or R7 is C3-C6-cycloalkyl;
R8 is C1-C6-alkyl, wherein the C1-C6-alkyl group is unsubstituted or mono- or polysubstituted identically or differently by halogen;
or a diastereomer, an enantiomer, a metabolite, a salt, a solvate, a solvate of the salt thereof.